Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Monoclonal Gammopathy of Undetermined Significance (MGUS) is considered pre-multiple myeloma. Most oncologists tell their newly diagnosed MGUS patients to “watch and wait.” Conventional oncology doesn’t consider MGUS to be cancer and therefore has no therapies to offer MGUS patients so the only option is to monitor this pre-MM “blood disorder.”
Needless to say, many newly diagnosed MGUS patients don’t want to just watch and wait.
When I read articles like this is, my fear is that MGUS patients will be talked into beginning an FDA approved MM chemotherapy regimen. And like SMM patients who also undergo some sort of induction chemotherapy, it is probable that pre-myeloma patient’s m-spike and other diagnostic markers will return to normal.
In other words, the patient will feel that he/she is slowing his/her march to full-blown MM. And to a large degree, this is true. Pre-MM patients can slow their progress to a diagnosis of frank MM.
Then again, that’s not really the goal of pre-myeloma patients, is it? The point is that pre-MM patients want to live as long and as high-quality a life as they can. I think we all want to live as long and as high quality a life as we can.
Once anyone-be they newly diagnosed pre-MM or frank MM begings chemotherapy, he or she begins their march toward multi-drug resistance (MDR). The sooner you start chemo, the sooner you reach MDR.
My solution is to undergo evidence-based, non-toxic therapies, all that have shown the ability to reduce one’s risk of multiple myeloma. Anti-MM nutrition, supplementation and lifestyle therapes, to name a few, will slow a person’s march toward MM while also not beginning the march toward MDR.
To learn more about evidence-based, non-toxic MM therapies, scroll down the page, post a question or comment and I will reply to you ASAP.
“People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five years, a study of blood serum immune markers reports.
This finding warrants annual blood testing for these people, researchers wrote in the study “Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma,” published in the journal JAMA Oncology.
Historically, people diagnosed with MGUS are classified as high, intermediate, or low risk. Individuals with high-risk MGUS are considered viable candidates for treatments that may prevent progression, whereas those with low or intermediate risk are typically given standard care by their primary care physicians.
The problem with this classification, an editorial published alongside the study explained, is that it “presupposes that the risk factors remain stable over the life of the disease.”
In other words, because pre-cancerous cells are continuously dividing and changing, a person’s risk of progression to multiple myeloma may change over time — but patients with MGUS are often given a risk score based on a single measurement at one point in time, and that score can hold for years…
Importantly, about 60% patients with MGUS progression met the criteria for multiple myeloma up to five years before their diagnosis, supporting “annual blood testing and risk assessment for all individuals with MGUS or light-chain MGUS,” researchers wrote in their study.
“This study … provides an important and biologically relevant concept that risk features are not stagnant, and that patients with MGUS may evolve over time,” the authors of the editorial wrote.
“If this scenario is to be confirmed in additional studies, it would require rethinking of our strategy to follow these patients as well as development of strategies to prevent progression not only in high-risk patients but also in patients at intermediate to low risk of progression,” they added.”